UPDATE on MedDay Biotin study for progressive multiple sclerosis.

Abstract presented in oral session at the European Academy of Neurology Saturday June 20, 2015:
http://ipp.netkey.at/ean/ean2015/index.php?p=recorddetail&rid=890ed356ff1448d46671fefdd58898b5#presedf003ebd948a472a05aa407d8abb021

MedDay and DSM announce a partnership to produce pharmaceutical grade Biotin to treat progressive multiple sclerosis
http://www.dsm.com/corporate/media/informationcenter-news/2015/06/2015-06-17-medday-and-dsm-announce-a-partnership-to-produce-pharmaceutical-grade-d-biotin-to-treat-progressive-multiple-sclerosis.html

http://www.medday-pharma.com/news-and-events/medday-reports-additional-positive-data-of-its-pivotal-phase-iii-study-with-md1003-in-patients-with-progressive-multiple-sclerosis/

MedDay reports additional positive data of its pivotal Phase III study with MD1003 in patients with Progressive Multiple Sclerosis